Aug 07, 2019 / 08:30PM GMT
Operator
Good afternoon, ladies and gentlemen, and welcome to the Sunesis Pharmaceuticals Second Quarter 2019 Earnings Call. (Operator Instructions) As a reminder, this conference call is being recorded. I would now like to turn the call over to your host, Mr. Willie Quinn, Chief Financial Officer and Senior Vice President, Corporate Development. The floor is yours, sir.
William P. Quinn - Sunesis Pharmaceuticals, Inc. - Senior VP of Finance & Corporate Development and CFO
Welcome, everyone. Thank you for joining us. With me today are Dayton Misfeldt, Interim Chief Executive Officer; Judy Fox, Chief Scientific Officer, Executive Vice President, Research and Development; Par Hyare, Senior Vice President, Commercial; and Deepali Suri, Vice President, Clinical Operations. Dayton will review recent corporate events. Judy will provide more details on the vecabrutinib program, and I will provide a brief financial overview of second quarter 2019. We will then open the call for questions, for which we will all be available. Before we begin, let me remind you that during today
Q2 2019 Sunesis Pharmaceuticals Inc Earnings Call Transcript
Mar 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers